NCT03322384View on ClinicalTrials.gov

UCDCC#271: Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 17, 2018

Primary Completion Date

February 24, 2020

Study Completion Date

April 8, 2020

Conditions
Advanced Solid TumorsLymphoma
Interventions
DRUG

epacadostat

Epacadostat will be administered orally, in pill form, twice daily until disease progression.

DRUG

SD-101

Four milligrams of SD-101 will be delivered into the treatment lesion by intralesional injection on days 1, 8, 15, 22, and 29.

RADIATION

Radiotherapy

Radiotherapy will be delivered to the treatment lesion during the first week of ERS therapy.

Trial Locations (1)

95817

University of California Davis Comprehensive Cancer Center, Sacramento

All Listed Sponsors
lead

University of California, Davis

OTHER

NCT03322384 - UCDCC#271: Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With Lymphoma | Biotech Hunter | Biotech Hunter